JP6055777B2 - クレアチン組成物水溶液の製造方法 - Google Patents
クレアチン組成物水溶液の製造方法 Download PDFInfo
- Publication number
- JP6055777B2 JP6055777B2 JP2013543039A JP2013543039A JP6055777B2 JP 6055777 B2 JP6055777 B2 JP 6055777B2 JP 2013543039 A JP2013543039 A JP 2013543039A JP 2013543039 A JP2013543039 A JP 2013543039A JP 6055777 B2 JP6055777 B2 JP 6055777B2
- Authority
- JP
- Japan
- Prior art keywords
- creatine
- water
- composition
- aqueous solution
- beverage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 title claims description 313
- 229960003624 creatine Drugs 0.000 title claims description 155
- 239000006046 creatine Substances 0.000 title claims description 155
- 239000000203 mixture Substances 0.000 title claims description 82
- 238000004519 manufacturing process Methods 0.000 title claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 63
- LELOWRISYMNNSU-UHFFFAOYSA-N hydrogen cyanide Chemical compound N#C LELOWRISYMNNSU-UHFFFAOYSA-N 0.000 claims description 38
- 239000000843 powder Substances 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 30
- 239000007864 aqueous solution Substances 0.000 claims description 27
- 238000006243 chemical reaction Methods 0.000 claims description 23
- MEJYXFHCRXAUIL-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;hydrate Chemical compound O.NC(=N)N(C)CC(O)=O MEJYXFHCRXAUIL-UHFFFAOYSA-N 0.000 claims description 19
- 229960004826 creatine monohydrate Drugs 0.000 claims description 19
- 239000007789 gas Substances 0.000 claims description 18
- 239000013078 crystal Substances 0.000 claims description 16
- 235000013361 beverage Nutrition 0.000 claims description 14
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 claims description 12
- 239000012535 impurity Substances 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 6
- MBBREGJRSROLGD-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound NC(=N)N(C)CC(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O MBBREGJRSROLGD-UHFFFAOYSA-N 0.000 claims description 4
- DLNGCCQFGNSBOP-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;2-oxopropanoic acid Chemical compound CC(=O)C(O)=O.NC(=N)N(C)CC(O)=O DLNGCCQFGNSBOP-UHFFFAOYSA-N 0.000 claims description 4
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 claims description 4
- 210000004211 gastric acid Anatomy 0.000 claims description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
- 239000011707 mineral Substances 0.000 claims description 4
- 235000011496 sports drink Nutrition 0.000 claims description 4
- 239000008399 tap water Substances 0.000 claims description 4
- 235000020679 tap water Nutrition 0.000 claims description 4
- 235000014171 carbonated beverage Nutrition 0.000 claims description 3
- 235000016213 coffee Nutrition 0.000 claims description 3
- 235000013353 coffee beverage Nutrition 0.000 claims description 3
- 235000013365 dairy product Nutrition 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- 235000013616 tea Nutrition 0.000 claims description 3
- 235000012174 carbonated soft drink Nutrition 0.000 claims description 2
- 235000020965 cold beverage Nutrition 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 241001122767 Theaceae Species 0.000 claims 1
- 208000006673 asthma Diseases 0.000 description 45
- 241000700199 Cavia porcellus Species 0.000 description 31
- 239000002504 physiological saline solution Substances 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 238000000034 method Methods 0.000 description 15
- 238000002360 preparation method Methods 0.000 description 15
- 238000012360 testing method Methods 0.000 description 14
- 241000700198 Cavia Species 0.000 description 13
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
- -1 cyanide compound Chemical class 0.000 description 8
- 230000000977 initiatory effect Effects 0.000 description 8
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 7
- 230000006698 induction Effects 0.000 description 6
- 239000003513 alkali Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- AMHZIUVRYRVYBA-UHFFFAOYSA-N 2-(2-amino-4,5-dihydroimidazol-1-yl)acetic acid Chemical compound NC1=NCCN1CC(O)=O AMHZIUVRYRVYBA-UHFFFAOYSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000011976 maleic acid Substances 0.000 description 4
- FJLBFSROUSIWMA-UHFFFAOYSA-N metyrapone Chemical compound C=1C=CN=CC=1C(C)(C)C(=O)C1=CC=CN=C1 FJLBFSROUSIWMA-UHFFFAOYSA-N 0.000 description 4
- 229960004465 metyrapone Drugs 0.000 description 4
- 230000004202 respiratory function Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 229960000582 mepyramine Drugs 0.000 description 3
- YECBIJXISLIIDS-UHFFFAOYSA-N mepyramine Chemical compound C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 YECBIJXISLIIDS-UHFFFAOYSA-N 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- JXYWFNAQESKDNC-BTJKTKAUSA-N (z)-4-hydroxy-4-oxobut-2-enoate;2-[(4-methoxyphenyl)methyl-pyridin-2-ylamino]ethyl-dimethylazanium Chemical compound OC(=O)\C=C/C(O)=O.C1=CC(OC)=CC=C1CN(CCN(C)C)C1=CC=CC=N1 JXYWFNAQESKDNC-BTJKTKAUSA-N 0.000 description 2
- MBSCHHMCRIMBDZ-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;nitric acid Chemical compound O[N+]([O-])=O.NC(=N)N(C)CC(O)=O MBSCHHMCRIMBDZ-UHFFFAOYSA-N 0.000 description 2
- PEXCMMDHBIFUIJ-UHFFFAOYSA-N 2-[carbamimidoyl(methyl)amino]acetic acid;sulfuric acid Chemical compound OS(O)(=O)=O.NC(=N)N(C)CC(O)=O PEXCMMDHBIFUIJ-UHFFFAOYSA-N 0.000 description 2
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000723377 Coffea Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 108010077895 Sarcosine Proteins 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000001364 causal effect Effects 0.000 description 2
- 239000013065 commercial product Substances 0.000 description 2
- JQIVVNGNZVUVJC-UHFFFAOYSA-N creatine methyl ester Chemical compound COC(=O)CN(C)C(N)=N JQIVVNGNZVUVJC-UHFFFAOYSA-N 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 229940050410 gluconate Drugs 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-M leucinate Chemical compound CC(C)CC(N)C([O-])=O ROHFNLRQFUQHCH-UHFFFAOYSA-M 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940018203 pyrilamine maleate Drugs 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 229940048098 sodium sarcosinate Drugs 0.000 description 2
- ZUFONQSOSYEWCN-UHFFFAOYSA-M sodium;2-(methylamino)acetate Chemical compound [Na+].CNCC([O-])=O ZUFONQSOSYEWCN-UHFFFAOYSA-M 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- VXMDOKODOQETRU-UHFFFAOYSA-N 2-[(4-amino-2,5-dihydro-1H-1,3,5-triazin-6-ylidene)-methylazaniumyl]acetate Chemical compound C\[N+](CC([O-])=O)=C1\NCN=C(N)N1 VXMDOKODOQETRU-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000006835 Lamins Human genes 0.000 description 1
- 108010047294 Lamins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- UFUWQSYRGLMLKP-UHFFFAOYSA-N creatine ethyl ester Chemical compound CCOC(=O)CN(C)C(N)=N UFUWQSYRGLMLKP-UHFFFAOYSA-N 0.000 description 1
- 229940124446 critical care medicine Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000008236 heating water Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000005053 lamin Anatomy 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940087646 methanolamine Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
- A23V2250/306—Creatine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Immunology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- General Preparation And Processing Of Foods (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Tea And Coffee (AREA)
- Non-Alcoholic Beverages (AREA)
Description
先にも述べたが、体内に摂取するクレアチン組成物と体内の胃酸が反応し、シアン化水素ガスが発生することが推測され、更に、クレアチン組成物を溶解させる水の温度とも何かしらの関連があることが推測される。
(1)クレアチン被験物質溶液の調製
先ず、本実施例2では、クレアチン被験物質溶液及び対照実験用溶液を調製した。クレアチン被験物質溶液を調製する際に使用したクレアチン組成物及び媒体は次に示す表2の通りである。
対照実験用溶液については、表2に示した0.5w/v%メチルセルロース400溶液(常温)をそのまま使用した。
後述する実施例5及び6にて使用する抗原含有生理食塩水溶液(1w/v%及び2w/v%)、メチラポン生理食塩水溶液及びピリラミンマレイン酸生理食塩水溶液の調製について次に説明する。
先ず、抗原としては、シグマアルドリッチ社のオボ(卵白)アルブミン(以下、「OVA」とする。)を使用した。調製は、OVAを秤量した後、生理食塩水(大塚製薬製)を使用して、1w/v%及び2w/v%のOVA含有生理食塩水溶液となるように調製した。調製については、用時調製、即ち、後述する経口投与実験(実施例5及び6参照)毎に随時調製するものとする。
使用するメチラポンは、シグマアルドリッチ社のものを使用した。調製は、メチラポンを秤量した後、生理食塩水(大塚製薬製)を使用して、10mg/mLの濃度となるようにメチラポン生理食塩水溶液を調製した。なお、調製については、上記OVA含有生理食塩水溶液同様用時調製とした。
使用するピリラミンマレイン酸塩は、シグマアルドリッチ社のものを使用した。調製は、ピリラミンマレイン酸塩を秤量した後、生理食塩水(大塚製薬製)を使用して、10mg/mLの濃度となるようにメチラポン生理食塩水溶液を調製した。なお、調製については、上記OVA含有生理食塩水溶液同様、用時調製とした。
後述の実施例5及び6に係る試験の前に、実施例2にて調製したクレアチン被験物質溶液及び対照試験用溶液を、2匹のモルモット(九動株式会社より提供)にそれぞれ経口投与した。以下、クレアチン被験物質溶液を投与したモルモットを「クレアチン喘息モデルモルモット」と称し、対照試験用溶液を投与したモルモットを「対照喘息モデルモルモット」と称する。
実施例4にてクレアチン被験物質溶液を投与したモルモット(クレアチン喘息モデルモルモット)及び対照実験用溶液を投与したモルモット(対照喘息モデルモルモット)を、それぞれポリプロピレン製コンテナに収容した後、実施例3にて調製した1w/v%のOVA含有生理食塩水溶液を、超音波ネブライザを用いて霧化させ、前記OVA含有生理食塩水溶液を1日あたり10分間かつ連続8日間吸入させた。このようにして喘息モデルモルモットを作製した。
実施例5にて作製したクレアチン喘息モデルモルモット及び対照喘息モデルモルモットに対して、最終感作の1週間後、呼吸機能測定用チャンバに収容及び保定し、その後、超音波ネブライザを用いて、実施例3にて調製した2w/v%のOVA含有生理食塩水溶液を霧化させたものを5分間吸入させることにより、抗原抗体反応を惹起させた。該惹起約24時間(前後1時間)前及び約1時間(前後5分)前に、実施例3で調製したメチラポン生理食塩水溶液を後肢末梢静脈内に、該惹起30分前に、実施例3で調製したピリラミンマレイン酸生理食塩水溶液を腹腔内にそれぞれの喘息モデルモルモットに投与した。
本実施例7においては、クレアチン喘息モデルモルモット及び対照喘息モデルモルモットに対して、総合呼吸機能解析システム(Pulmos−I、株式会社エム・アイ・ピー・エス製)を使用して、気道抵抗(specific airway resistance, sRaw)を測定した。sRaw値の測定については、実施例6における抗原抗体反応の惹起開始1分後、前記抗体反応の惹起開始約2、4、5、6、7、8及び22(〜24)時間後に測定した。各測定時間におけるsRawは、モルモット100呼吸分の平均値とした。なお、各モルモットに対して、実施例6におけるメチラポン生理食塩水溶液投与前に、呼吸機能測定用チャンバに収容及び保定する操作を少なくとも1回は行い、前記チャンバに対する馴化を実施した。
上記実施例7において算出したsRaw増加率において、抗原抗体反応の惹起開始1分後のsRaw増加率を、即時型喘息反応(Immediate Airway Response。以下「IAR」とする。)の評価指標とした。
Claims (4)
- 常温若しくは冷温の飲料と混合させて経口摂取するクレアチン組成物水溶液の製造方法であって、
水を80〜100℃に加温する段階と、
製品状態のクレアチン組成物を1秒〜10分かけて、前記加温した水に溶解させてクレアチン組成物水溶液を調製する段階とを備え、
前記クレアチン組成物が、クレアチン一水和物、クレアチン無水物、クレアチンリン酸塩、クレアチンピルビン酸塩、クレアチンクエン酸塩のうちいずれか1つの結晶体粉末又はそれらを2つ以上組み合わせて成るものであり、
前記クレアチン組成物水溶液を常温若しくは冷温の前記飲料と混合させて経口摂取したときの、シアン化合物系の不純物と、胃酸の主成分である塩酸との反応によるシアン化水素ガスの発生が抑えられた、クレアチン組成物水溶液の製造方法。 - 前記飲料が、前記クレアチン組成物水溶液を調製する際に用いた水と同じ、若しくは異なる水である請求項1に記載のクレアチン組成物水溶液の製造方法。
- 前記水が、水道水、蒸留水、ミネラルウォータ類から選択される請求項2に記載のクレアチン組成物水溶液の製造方法。
- 前記飲料がジュース、スポーツドリンク、牛乳若しくは乳製品類、お茶類、コーヒー、炭酸飲料、又は清涼飲料水のうちいずれかから選択される請求項1に記載のクレアチン組成物水溶液の製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011246208 | 2011-11-10 | ||
JP2011246208 | 2011-11-10 | ||
PCT/JP2012/079105 WO2013069764A1 (ja) | 2011-11-10 | 2012-11-09 | クレアチン組成物の摂取方法及び該摂取方法にて使用するクレアチン組成物並びに前記クレアチン組成物を使用して成るクレアチン含有薬剤及び食品 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015075744A Division JP2015165803A (ja) | 2011-11-10 | 2015-04-02 | 経口摂取用クレアチン組成物及び前記経口摂取用クレアチン組成物を使用して成るクレアチン含有食品 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2013069764A1 JPWO2013069764A1 (ja) | 2015-04-02 |
JP6055777B2 true JP6055777B2 (ja) | 2016-12-27 |
Family
ID=48290132
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013543039A Active JP6055777B2 (ja) | 2011-11-10 | 2012-11-09 | クレアチン組成物水溶液の製造方法 |
JP2015075744A Pending JP2015165803A (ja) | 2011-11-10 | 2015-04-02 | 経口摂取用クレアチン組成物及び前記経口摂取用クレアチン組成物を使用して成るクレアチン含有食品 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2015075744A Pending JP2015165803A (ja) | 2011-11-10 | 2015-04-02 | 経口摂取用クレアチン組成物及び前記経口摂取用クレアチン組成物を使用して成るクレアチン含有食品 |
Country Status (5)
Country | Link |
---|---|
US (2) | US9757347B2 (ja) |
EP (1) | EP2777700B1 (ja) |
JP (2) | JP6055777B2 (ja) |
CN (1) | CN104080448B (ja) |
WO (1) | WO2013069764A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN204243174U (zh) | 2014-10-21 | 2015-04-01 | 中兴通讯股份有限公司 | 一种天线结构 |
CN114391620A (zh) * | 2021-12-21 | 2022-04-26 | 宣城柏维力生物工程有限公司 | 一种增强运动表现的肌酸饮品及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3213666B2 (ja) | 1994-02-28 | 2001-10-02 | 治彦 末岡 | クレアチン飲料の製造方法 |
JP3595373B2 (ja) * | 1995-02-20 | 2004-12-02 | 治彦 末岡 | クレアチン飲料 |
DE19526236A1 (de) | 1995-07-18 | 1997-01-23 | Sueddeutsche Kalkstickstoff | Verfahren zur Herstellung von Kreatin bzw. Kreatin-monohydrat |
US5886040A (en) * | 1997-06-17 | 1999-03-23 | Amt Labs, Inc. | Creatine pyruvate salt with enhanced palatability |
JP3384539B2 (ja) * | 1997-09-05 | 2003-03-10 | 義之 内田 | 喘息治療剤 |
US5973005A (en) * | 1998-02-26 | 1999-10-26 | Bio-Bontanica, Inc. | Aqueous creatine solution and process of producing a stable, bioavailable aqueous creatine solution |
US20050085498A1 (en) * | 1998-05-28 | 2005-04-21 | Byrd Edward A. | Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate |
CN1098251C (zh) * | 1999-09-07 | 2003-01-08 | 天津天成制药有限公司 | 制备肌酸或肌酸-水合物的方法 |
JP2001131065A (ja) | 1999-11-05 | 2001-05-15 | Meiji Seika Kaisha Ltd | 体脂肪減少促進剤及び体脂肪減少促進用食品組成物 |
DE19962227A1 (de) | 1999-12-22 | 2001-06-28 | Basf Ag | Verfahren zur Reinigung von Kreatin |
AU2002237395B2 (en) * | 2001-03-02 | 2006-08-31 | The Howard Foundation | Compositions containing creatine and creatinine |
DE102006016227A1 (de) * | 2006-04-06 | 2007-10-11 | Degussa Gmbh | Verfahren zur Herstellung von Kreatin, Kreatin-Monohydrat oder Guanidinoessigsäure |
WO2007133673A2 (en) * | 2006-05-11 | 2007-11-22 | Avicena Group, Inc. | Methods of treating a neurological disorder with creatine monohydrate |
CA2690151C (en) | 2007-06-05 | 2016-05-24 | Phenolics, Llc | Enteric coated, soluble creatine and polyethylene glycol composition for enhanced skeletal uptake of oral creatine |
-
2012
- 2012-11-09 CN CN201280054805.3A patent/CN104080448B/zh active Active
- 2012-11-09 JP JP2013543039A patent/JP6055777B2/ja active Active
- 2012-11-09 EP EP12847729.6A patent/EP2777700B1/en active Active
- 2012-11-09 US US14/357,032 patent/US9757347B2/en active Active
- 2012-11-09 WO PCT/JP2012/079105 patent/WO2013069764A1/ja active Application Filing
-
2015
- 2015-04-02 JP JP2015075744A patent/JP2015165803A/ja active Pending
-
2017
- 2017-08-04 US US15/669,087 patent/US20170332687A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN104080448A (zh) | 2014-10-01 |
US9757347B2 (en) | 2017-09-12 |
EP2777700A1 (en) | 2014-09-17 |
JPWO2013069764A1 (ja) | 2015-04-02 |
JP2015165803A (ja) | 2015-09-24 |
CN104080448B (zh) | 2018-02-13 |
WO2013069764A1 (ja) | 2013-05-16 |
EP2777700A4 (en) | 2015-08-05 |
US20140328910A1 (en) | 2014-11-06 |
EP2777700B1 (en) | 2019-04-24 |
US20170332687A1 (en) | 2017-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6255079B2 (ja) | シトルリンおよびアルギニンを含有する即効性血中アルギニン濃度上昇型経口剤 | |
JP3548102B2 (ja) | 高血圧症予防・治療剤 | |
WO2007023931A1 (ja) | 血中アルコール濃度上昇抑制用組成物 | |
JP5053535B2 (ja) | 寝つきまたは寝起き改善用経口剤 | |
JPH01294631A (ja) | 糖尿性疾患治療予防剤及び飲食、し好物 | |
JP5128828B2 (ja) | 抗炎症剤及び抗酸化剤 | |
JP6055777B2 (ja) | クレアチン組成物水溶液の製造方法 | |
JP6944221B2 (ja) | Chp(シクロ−ヒスプロ)を含む骨損失疾患の予防、改善または治療用組成物 | |
JP2013060406A (ja) | 脳疲労改善用経口剤 | |
JP3736776B2 (ja) | 新規カルシウム組成物 | |
JPWO2008044770A1 (ja) | 4−ヒドロキシイソロイシンを含む胃排出抑制剤 | |
JP2011079789A (ja) | アンジオテンシンi変換酵素阻害剤 | |
JP3552075B2 (ja) | 易吸収性カルシウム組成物 | |
EP2821069A1 (en) | Enhancer for eating activity and/or gastrointestinal activity | |
JP2009102233A (ja) | 肥満防止剤及びそれを含有する飲食品 | |
JP2016121194A (ja) | 脳疲労改善用経口剤 | |
JP2005314435A (ja) | 循環器疾患治療剤および健康食品 | |
WO2022224776A1 (ja) | 脂質減少促進剤 | |
JP2012162566A (ja) | 抗炎症剤及び抗酸化剤 | |
JP2007320947A (ja) | 血糖値上昇抑制剤 | |
WO2006129353A1 (ja) | 新規な血圧上昇抑制剤 | |
JP2009298759A (ja) | α‐アミラーゼ阻害剤 | |
WO2007119502A1 (ja) | 便通改善剤 | |
JP5997425B2 (ja) | オルニチン含有組成物 | |
JP2006089449A (ja) | 脂肪吸収抑制剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20150106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150402 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150413 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20150515 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160907 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161205 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6055777 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |